Certolizumab pegol – new option in the treatment of psoriatic arthritis
It has been proven that tumor necrosis factor (TNF) plays an important role in the pathophysiology of psoriatic arthritis (PsA). TNF inhibitors have been demonstrated to improve the skin and joint manifestations of psoriasis. New possibilities of treatment of the disease have appeared due to availab...
Main Authors: | Maria Majdan, Anna Siwiec, Aleksandra Gryta |
---|---|
Format: | Article |
Language: | English |
Published: |
Termedia Publishing House
2014-07-01
|
Series: | Rheumatology |
Subjects: | |
Online Access: | http://www.termedia.pl/Certolizumab-pegol-new-option-in-the-treatment-of-psoriatic-arthritis,18,23171,1,1.html |
Similar Items
-
EFFICACY OF CERTOLIZUMAB PEGOL IN THE TREATMENT OF PSORIATIC ARTHRITIS
by: T. V. Korotaeva, et al.
Published: (2015-10-01) -
An evidence-based review of certolizumab pegol in the treatment of active psoriatic arthritis: place in therapy
by: Acosta-Felquer ML, et al.
Published: (2016-03-01) -
Safety and efficacy of certolizumab pegol in a real-life cohort of patients with psoriasis and psoriatic arthritis
by: Francesco Carubbi, et al.
Published: (2020-10-01) -
Multifocal tuberculosis on certolizumab pegol in a patient followed for rheumatoid arthritis
by: Emna Hannech, et al.
Published: (2021-06-01) -
Certolizumab pegol: new opportunities for treatment of moderate to severe plaque psoriasis
by: A. A. Kubanov, et al.
Published: (2019-12-01)